Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 USD | +0.78% | +9.36% | -19.18% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
Financials (USD)
Sales 2024 * | 832K | Sales 2025 * | 8.66M | Capitalization | 20.7M |
---|---|---|---|---|---|
Net income 2024 * | -41M | Net income 2025 * | -40M | EV / Sales 2024 * | 24.9 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.39 x |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-1.39
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.97% |
Latest transcript on Lumos Pharma, Inc.
1 day | +0.78% | ||
1 week | +9.36% | ||
Current month | +14.22% | ||
1 month | -10.61% | ||
3 months | -14.90% | ||
6 months | -10.14% | ||
Current year | -19.18% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 2.57 | +0.78% | 8 668 |
24-06-11 | 2.55 | +5.81% | 8,916 |
24-06-10 | 2.41 | -2.82% | 25,868 |
24-06-07 | 2.48 | -1.20% | 5,338 |
24-06-06 | 2.51 | +6.81% | 21,716 |
Delayed Quote Nasdaq, June 12, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.18% | 20.7M | |
+48.54% | 56.87B | |
+37.15% | 39.72B | |
-6.02% | 39.27B | |
-6.90% | 28.73B | |
+12.97% | 26.21B | |
-16.91% | 19.79B | |
+31.71% | 12.28B | |
+28.18% | 12.23B | |
+0.38% | 12.12B |
- Stock Market
- Equities
- LUMO Stock